Trial Profile
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms STARVE-PC
- 13 Oct 2021 Status changed from active, no longer recruiting to completed.
- 10 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2019 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.